We have observed
7 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 publication dated after
December 15, 2012).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
USE OF A COMPOSITION COMPRISING A POLY-ORGANOSILOXANE
METHOD FOR THE DIAGNOSIS AND/OR PROGNOSIS OF ACUTE RENAL DAMAGE
BETA-3 ADRENOCEPTOR AGONISTS FOR THE TREATMENT OF PULMONARY HYPERTENSION
METHOD FOR PREDICTING TREATMENT RESPONSE AND TEST FOR SAFE USE OF MESENCHYMAL STEM CELLS ON INFLAMMATORY DISEASES.
COMBINATIONS OF AGGREGATING PROTEINS AND MOLECULAR CHAPERONE PROTEINS FOR THE TREATMENT OF PROTEINOPATHIES OR CONFORMATIONAL DISEASES
METHOD FOR PREDICTING THE RESPONSE TO CHEMOTHERAPY TREATMENT IN PATIENTS SUFFERING FROM COLORECTAL CANCER
STABLE PHARMACEUTICAL FORMULATIONS OF CASPOFUNGIN